Patent ID: 8377964

Claim:
A method of treating a disorder of reduced motility of the gastrointestinal tract in a mammal, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (I): wherein: R 1 is C 3-5 alkyl, optionally substituted with —OH; and X is selected from (a) —C(O)OR 2 wherein R 2 is C 1-4 alkyl or —(CH 2 ) n -phenyl wherein n is 0 or 1; (b) —C(O)R 3 wherein R 3 is selected from: phenyl, optionally substituted with 1, 2, or 3 substituents selected from C 1-4 alkyl, halo, C 1-4 alkoxy, —CF 3 , —OCF 3 , —OCHF 2 , and —CN, C 1-5 alkyl, C 4-5 cycloalkyl, and —(CH 2 ) m -A wherein m is 0 or 1 and A is selected from amino, furanyl, thiophenyl, morpholinyl, tetrahydrofuranyl, pyridinyl, naphthalenyl, pyrrolyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, oxoazetidinyl, thiazolidinyl, 1,1-dioxo isothiazolidinyl, and 2,4-dimethylisoxazolyl; (c) —C(O)NR 4 R 5 wherein R 4 is hydrogen or C 1-3 alkyl, and R 5 is phenyl optionally substituted with 1, 2, or 3 substituents selected from C 1-4 -alkyl, halo, C 1-4 -alkoxy, —CF 3 , —OCF 3 , and —OCHF 2 ; (d) —C(O)C(R 6 R 7 )R 8 wherein R 6 is hydrogen or C 1-3 alkyl and R 7 is hydrogen, —OH, or C 1-3 alkyl; or R 6 and R 7 taken together form oxo or —(CH 2 ) 2 —; and R 8 is phenyl or cyclohexyl, wherein phenyl or cyclohexyl are optionally substituted with 1, 2, or 3 substituents selected from C 1-4 -alkyl, halo, C 1-4 -alkoxy, —CF 3 , —OCF 3 , —OCHF 2 , and —CN; (e) —C(O)C(HR 9 )OR 10 wherein R 9 is hydrogen or C 1-3 alkyl, and R 10 is phenyl optionally substituted with 1, 2, or 3 substituents selected from C 1-4 -alkyl, halo, C 1-4 -alkoxy, —CF 3 , —OCF 3 , and —OCHF 2 ; and (f) —S(O) 2 R 11 wherein R 11 is selected from C 1-3 alkyl, —CH 2 -phenyl, furanyl, thiophenyl, morpholinyl, tetrahydrofuranyl, pyridinyl, naphthalenyl, pyrrolyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, oxoazetidinyl, thiazolidinyl, 1,1-dioxo isothiazolidinyl, 2,4-dimethylisoxazolyl, and phenyl optionally substituted with 1, 2, or 3 substituents selected from C 1-4 -alkyl, halo, C 1-4 -alkoxy, —CF 3 , —OCF 3 , —OCHF 2 , and —CN; or a pharmaceutically-acceptable salt or stereoisomer thereof.